Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma - Trial NCT06376669
Access comprehensive clinical trial information for NCT06376669 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Timeline & Enrollment
Phase 2
Jun 01, 2024
Aug 01, 2030
Primary Outcome
Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels,Change in kidney function after PROTON-BASED SBRT treatment as assessed by estimated glomerular rate (eGFR) values
Summary
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on
 kidney function as well as other oncologic outcomes including local control, locoregional and
 systemic failure, progression free and overall survival.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06376669
Non-Device Trial